Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Rocket Pharmaceuticals, Inc.

RCKTNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 18, 2026Accepted Aug 18, 2026, 3:49 PM EDTFiling CIK 1281895Accession 0001959173-26-006169
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
ROCKET PHARMACEUTICALS, INC.
Issuer CIK
0001281895
SEC file number
001-36829
Phone
646-440-9100
Person for whose account securities are to be sold
Shah Gaurav
Relationships to issuer
Officer · Director
Street
350 FIFTH AVENUE
Street (continued)
SUITE 7530
City
NEW YORK
State / country code
NY
Postal code
10118

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common2,2937,753.55109,774,59708/18/2026NASDAQFidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name
Fidelity Brokerage Services LLC
Street
900 Salem Street
City
Smithfield
State / country code
RI
Postal code
02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common08/14/2026Restricted Stock VestingIssuer2,293N08/14/2026Compensation

Sales reported in the preceding three months

Sales reported in the preceding three months · 3 reported rows
SellerSecuritySale dateAmount soldGross proceeds
Gaurav ShahCommon05/19/20262,4097,261.69
Gaurav ShahCommon05/21/202655,684171,818.55
Gaurav ShahCommon08/13/20262,8379,592.18

Seller — prior-sale row 1, entry 1

Name
Gaurav Shah
Street
9 Cedarbrook Drive
City
Cranbury
State / country code
NJ
Postal code
08512

Seller — prior-sale row 2, entry 1

Name
Gaurav Shah
Street
9 Cedarbrook Drive,
City
Cranbury
State / country code
NJ
Postal code
08512

Seller — prior-sale row 3, entry 1

Name
Gaurav Shah
Street
9 Cedarbrook Drive
City
Cranbury
State / country code
NJ
Postal code
08512

Prior-sale reporting

Nothing to report for the preceding three months
N

Remarks

Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.

Notice signature

Notice date
08/18/2026
Signed
/s/ Louis Kurnick, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Gaurav Shah

Company context

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket's cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company’s integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities and extensive clinical experience in cardiac gene therapy.

Current securities

Historical securities (1)

Recent company filings

  1. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 6, 2026
  2. Regulation FD DisclosureSep 15, 2026
  3. 144 filingSep 11, 2026
  4. 25-NSE - filed by Nasdaq Stock Market LLC regarding ROCKET PHARMACEUTICALS, INC.Sep 2, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 27, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.